| Autor: |
John K. Botson, Kenneth Saag, Jeff Peterson, Katie Obermeyer, Yan Xin, Brian LaMoreaux, Lissa Padnick‐Silver, Supra Verma, Suneet Grewal, Amar Majjhoo, John R. P. Tesser, Michael E. Weinblatt |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
ACR Open Rheumatology, Vol 5, Iss 8, Pp 407-418 (2023) |
| Druh dokumentu: |
article |
| ISSN: |
2578-5745 |
| DOI: |
10.1002/acr2.11578 |
| Popis: |
Objective To assess 12‐month safety and efficacy of pegloticase + methotrexate (MTX) versus pegloticase + placebo (PBO) cotherapy in a PBO‐controlled, double‐blind trial (A randomized, double‐blind, placebo‐controlled, multicenter, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase [MIRROR RCT]). Methods Patients with uncontrolled gout (serum urate level [SU] ≥7 mg/dl, oral urate‐lowering therapy failure or intolerance, and presence of one or more gout symptoms [one or more tophi, two or more flares in 12 months, gouty arthropathy]) were randomized 2:1 to receive pegloticase (8‐mg infusion every 2 weeks) with blinded MTX (oral 15 mg/week) or PBO for 52 weeks. Efficacy end points included proportion of responders (SU level |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Plný text